Current issue #33, 2016

Pharma market players worried about balance of power

A year ago, the Russian pharmaceutical leaders were a short way off “burying” the debt-stricken SIA International. Currently, they are worried to see the nearly bankrupt company re-emerging as a top player. The company’s ambitious plans aimed at strengthening its position and returning to the top distributor ranks inspire both the competitors’ respect and envy. However, the news regarding the fact that the pharmacy chains in which SIA International has a 25% share have received pharmaceutical licenses and are penetrating the market at a high rate opening a new pharmacy unit per day made the competitors really agitated. Experts, in turn, have not doubts that this project is a fat chance for the company’s owner to start a big game.

[PharmVestnik # 33, 18/10/2016, p. 1, cont’d p. 5]

Crimean health sector gets adjusted to Russian legislation

The Crimean healthcare upgrading process it not an easy one. The main challenge is to develop a beneficial population coverage system from scratch as such system has been nonexistent before the Republic of Crimea has joined Russia. At this point, it is required not only to develop and implement explicit mechanisms for the population demand calculation but also to change the ideology of the entire Crimean medical community. This issue was on top of the agenda of the forum “Crimean healthcare’2016” hosted by DSM Group in Simferopol.

[PharmVestnik # 33, 18/10/2016, p. 2]

Survival of the fittest

Minpromtorg promotes Russian pharma industry innovations

Within the framework of demonstrating Russian R&D results obtained in the course of the State Target Program “Pharma-2020” implementation, the Ministry of Industry and Trade (Minpromtorg) launched a promotion program in the project office format. Its main objective is to help Russian developers analyze the market, assess the prospects and patentability of innovative solutions as well as technological capabilities and economic potential for their scaleup.

[PharmVestnik # 33, 18/10/2016, p. 3]

Sovaldi of discord

Gilead’s originator drug generics move close to Russia

The first generic of sofosbuvir, a hepatitis C treatment, was registered in Belarus. Gilead that is the originator drug owner, did not patent the drug in that country, and, in accordance with the international law, Belarus has the right to manufacture and register the drug. The drug price in that country turned out to be high...